With US approval to treat first-line and relapsed/refractory chronic lymphocytic leukemia, BeiGene, Ltd.’s Brukinsa appears well positioned to compete with AbbVie Inc./Johnson & Johnson’s established BTK inhibitor Imbruvica (ibrutinib). Multiple market analysts predicted significant revenue growth for Brukinsa with this latest approval in the largest leukemia setting.
BeiGene announced US Food and Drug Administration approval for Brukinsa (zanubrutinib) late on 19 January in CLL and small lymphocytic...







